Lineage Cell Therapeutics, Inc. 8-K Filing
Ticker: LCTX · Form: 8-K · Filed: Nov 24, 2025 · CIK: 876343
| Field | Detail |
|---|---|
| Company | Lineage Cell Therapeutics, Inc. (LCTX) |
| Form Type | 8-K |
| Filed Date | Nov 24, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $5 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lineage Cell Therapeutics, Inc. (ticker: LCTX) to the SEC on Nov 24, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $5 million (therapy program. This event triggered a $5 million milestone payment to Lineage, which is).
How long is this filing?
Lineage Cell Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 551 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-11-24 06:49:07
Key Financial Figures
- $5 million — therapy program. This event triggered a $5 million milestone payment to Lineage, which is
Filing Documents
- lctx-20251120.htm (8-K) — 41KB
- 0001193125-25-291979.txt ( ) — 140KB
- lctx-20251120.xsd (EX-101.SCH) — 23KB
- lctx-20251120_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously reported, in December 2021, Lineage Cell Therapeutics, Inc. ("we," "us," "our," the "Company," or "Lineage"), entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the "Roche Agreement") under which our lead cell therapy program known as OpRegen (also known as RG6501) is being developed for the treatment of ocular disorders, including geographic atrophy ("GA") secondary to age-related macular degeneration ("AMD"). OpRegen is currently being evaluated in a Phase 2a multicenter clinical trial, known as "GAlette", in patients with GA secondary to AMD. On November 20, 2025, the first development milestone under the Roche Agreement was achieved based on manufacturing and clinical advancements related to the OpRegen cell therapy program. This event triggered a $5 million milestone payment to Lineage, which is expected to be received by us within 30 days. As previously reported, approximately 24.1% and 21.5% of the milestone payment will be paid to the Israel Innovation Authority and to Hadasit Medical Research and Development Ltd. ("Hadasit"), respectively, in accordance with the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and in accordance with agreements between our subsidiary, Cell Cure Neuroscience Ltd., and Hadasit, respectively.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lineage Cell Therapeutics, Inc. Date: November 24, 2025 By: /s/ George A. Samuel III Name: Title: George A. Samuel III General Counsel and Corporate Secretary